CSPC Pharmaceutical Group Limited — Board/Management Information 2012

Jan 20, 2012

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this document, makes no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this document.

==> picture [273 x 88] intentionally omitted <==

APPOINTMENT OF EXECTUIVE DIRECTOR

The Board of Directors (the “Board”) of China Pharmaceutical Group Limited (the “Company”) is pleased to announce the appointment of Mr. Wang Zhenguo as executive director of the Company with effect from 20 January 2012.

Mr. Wang Zhenguo, aged 42, joined a member of our Group in 1991. He is currently the general manager of a member of the Group engaged in the production and sales of finished drug products. Mr. Wang holds a bachelor degree in chemistry from Nankai University and has more than 20 years of technical and management experience in the pharmaceutical industry. Mr. Wang has not held any directorship in any public listed companies in the last three years.

There is no service contract entered into between the Company and Mr. Wang. He is not appointed for a specific term but is subject to retirement by rotation and re-election at the annual general meetings of the Company in accordance with the articles and association of the Company. Mr. Wang is entitled to receive a monthly salary of RMB49,316 and an annual director’s fee of HK$60,000. He is also eligible to receive performance related discretionary bonus to be determined by the Board. His emoluments were determined having giving consideration to the prevailing market practice, the Company’s remuneration policy and his level of responsibility.

As at the date of this announcement, Mr. Wang does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance nor any relationship with any directors, senior management, substantial shareholders or controlling shareholders of the Company. Save as disclosed above, Mr.

Wang confirmed that there is no other information required to be disclosed under Rule 13.51(2) of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited and there is no other matter relating to his appointment which needs to be brought to the attention of the shareholders of the Company.

By order of the Board Cai Dongchen Chairman

China Parmaceutical Group Limited

Hong Kong, 20 January 2012

As at the date of this announcement, the Board of the Company comprises Mr. Cai Dongchen, Mr. Feng Zhenying, Mr. Chak Kin Man, Mr. Pan Weidong, Mr. Zhao John Huan, Mr. Wang Shunlong, Mr. Wang Huaiyu, Mr. Lu Jianmin and Mr. Wang Zhenguo as executive directors; Mr. Lee Ka Sze, Carmelo as non-executive director; and Mr. Huo Zhenxing, Mr. Qi Moujia, Mr. Guo Shichang and Mr. Chan Siu Keung, Leonard as independent non-executive directors.